trial

Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

NCTId NCT05890768
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Withdrawn
Enrollment 0 (actual)
Sponsored by University of New Mexico
Primary completion 2024-02-28
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2023-05-11
Primary completion
2024-02-28
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Lumateperone (Caplyta)Risperidone

Sponsors

University of New MexicoLead Sponsor

Investigators

1
Juan Bustillo, MDPrincipal Investigator

Sites

1 total
Albuquerque, United States

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE4
Primary Completion Date
2024-02-28
Status
WITHDRAWN
relationships
The graph out of here
drug
Lumateperone (Caplyta)
drug
Risperidone
drug
lead_sponsor
University of New Mexico
company
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Juan Bustillo, MD
person